September 2022
Article
Pacing and Clinical Electrophysiology

Cost of Cardiac Stereotactic Body Radioablation Therapy versus Catheter Ablation for Treatment of Ventricular Tachycardia

By: Chen Wei, Michelle Boeck, Pierre C. Qian, Todd Vivenzio, Zoe Elizee, Jeremy S. Bredfeldt, Robert S. Kaplan, Usha Tedrow, Raymond Mak and Paul C. Zei

Format:Print

Abstract

Cardiac SBRT is a novel way of treating refractory ventricular tachycardia (VT) that may be less costly than catheter ablation, owing to its noninvasive, outpatient nature. We applied time-driven activity-based costing to both procedures. The direct and total procedural costs of cardiac SBRT were 49% and 54% less than those of VT ablation. Including hospitalization expenses, cardiac SBRT is at least $27,000 less expensive to deliver than VT ablation. Conclusion: Time-driven activity-based costing (TDABC) can be a helpful tool for assessing healthcare costs and informing the reimbursement for novel treatment approaches.

Keywords

Health Care and Treatment; Activity Based Costing and Management; Cost; Health Industry

Citation

Wei, Chen, Michelle Boeck, Pierre C. Qian, Todd Vivenzio, Zoe Elizee, Jeremy S. Bredfeldt, Robert S. Kaplan, Usha Tedrow, Raymond Mak, and Paul C. Zei. "Cost of Cardiac Stereotactic Body Radioablation Therapy versus Catheter Ablation for Treatment of Ventricular Tachycardia." Pacing and Clinical Electrophysiology 45, no. 9 (September 2022): 1005–1179.